REG - OptiBiotix Health - Joint development agreement signed with Royal DSM <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

05/04/2016 07:05

RNS Number : 1258U
OptiBiotix Health PLC
05 April 2016
5 April 2016
OptiBiotix Health plc
("OptiBiotix"or "the Company")
Joint Development Agreement signed with Royal DSM
OptiBiotixHealthplc(AIM:OPTI),alifesciencesbusinessdevelopingproductstotackleobesity,highcholesteroland
diabetes, announcesthatithas entered into a joint development agreement with Royal DSM. The agreement allows for collaboration between both parties to develop new products using OptiBiotix's OptiBiotic technology platform.
Royal DSM is a global science based company active in health, nutrition and materialswith approximately 25,000 employees and annual net sales in the region of 10billion. Its Nutritional Products business is one of the world's leading suppliers of vitamins, carotenoids, nutritional lipids and other ingredients in the food, pharmaceutical and personal care industries.
If successful, the agreement allows both parties to agree commercial terms such that OptiBiotix grants an exclusive licence to DSM in the DSM field, and an option to license in other fields, in return for royalty payments on sales of future products.
StephenO'Hara,CEOofOptiBiotix,commented:"We are pleased to announce the signing of a joint development agreement with DSM, one of the world's leading suppliers of nutritional ingredients. We believe that OptiBiotix's strong science base together with DSM's innovation focus and global reach will help both companies bring better science and better health to people around the world."
For further information, please contact:
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7148 7900
Liam Murray 

Avi Robinson



Hybridan LLP (Joint Broker)
Tel: 020 3764 2341
Claire Louise Noyce



PeterhouseCorporateFinanceLtd(JointBroker)
Tel: 020 7469 0936
Lucy Williams

Duncan Vasey



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002
About OptiBiotix Health PLC - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
About Royal DSM www.dsm.com
DSM - Bright Science. Brighter Living.
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about 10billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCBLGDSGBGBGLS